No Data
No Data
No Data
No Data
No Data
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
GlobeNewswireApr 19 04:05
Lumos Pharma's LUM-201 Receives 'Buy' Rating on Strong Market Position and Promising Trial Outcomes
TipRanksMar 20 23:45
Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
Lumos Pharma Announces USPTO Has Granted Patent Protection For Novel Formulation Of LUM-201, Extending Exclusivity To 2042
BenzingaMar 20 20:06
Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceMar 10 20:31
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
HC Wainwright & Co. analyst Edward White reiterates Lumos Pharma with a Buy and maintains $28 price target.
Analyst UpgradesMar 8 19:52
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
TipRanksMar 8 19:30
No Data
No Data